Tredje AP fonden Boosts Stake in Boston Scientific Corporation $BSX

Tredje AP fonden increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,146,889 shares of the medical equipment provider’s stock after buying an additional 76,201 shares during the period. Boston Scientific accounts for approximately 0.8% of Tredje AP fonden’s portfolio, making the stock its 26th largest holding. Tredje AP fonden’s holdings in Boston Scientific were worth $109,356,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the stock. Handelsbanken Fonder AB boosted its position in shares of Boston Scientific by 11.7% during the 4th quarter. Handelsbanken Fonder AB now owns 2,520,119 shares of the medical equipment provider’s stock worth $240,293,000 after purchasing an additional 263,737 shares during the period. AMF Tjanstepension AB boosted its position in shares of Boston Scientific by 5.1% during the 4th quarter. AMF Tjanstepension AB now owns 952,950 shares of the medical equipment provider’s stock worth $90,864,000 after purchasing an additional 46,538 shares during the period. Capstone Capital Management Ltd purchased a new position in shares of Boston Scientific during the 4th quarter worth approximately $581,000. Profund Advisors LLC boosted its position in shares of Boston Scientific by 21.9% during the 4th quarter. Profund Advisors LLC now owns 25,269 shares of the medical equipment provider’s stock worth $2,409,000 after purchasing an additional 4,542 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Boston Scientific by 9.3% during the 4th quarter. ProShare Advisors LLC now owns 306,169 shares of the medical equipment provider’s stock worth $29,193,000 after purchasing an additional 26,021 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Evercore lowered their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. The Goldman Sachs Group decreased their price target on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.83.

Boston Scientific Stock Performance

Shares of BSX stock opened at $55.86 on Tuesday. The stock has a market capitalization of $83.02 billion, a PE ratio of 23.37, a P/E/G ratio of 0.97 and a beta of 0.62. The firm has a 50 day moving average of $63.06 and a two-hundred day moving average of $81.33. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific launched a $2 billion accelerated share repurchase, which should reduce share count and support earnings per share. The move signals management confidence and adds a near-term catalyst for the stock. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also announced a $1.5 billion strategic investment in MiRus, taking an approximately 34% stake and gaining an exclusive option to buy MiRus’ TAVR business. Investors view this as a way for Boston Scientific to expand into the fast-growing structural heart market. Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
• Positive Sentiment: Several analysts reiterated bullish views, including Needham and BTIG, both of which kept buy ratings and highlighted upside potential in BSX shares. Analyst rating updates
• Neutral Sentiment: Boston Scientific was also mentioned on a list of top analyst picks for the week, reflecting continued positive sentiment around the name. 3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
• Negative Sentiment: One notable offset is that Bank of America lowered its price target on BSX, even while keeping a buy rating, suggesting some caution about valuation or near-term expectations. Bank of America price target update

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.